Metabolic and endocrine effects of valproic acid chronic treatment

被引:101
作者
Belcastro, Vincenzo [1 ]
D'Egidio, Claudia [2 ]
Striano, Pasquale [3 ]
Verrotti, Alberto [4 ]
机构
[1] St Anna Hosp, Neurol Unit, Dept Neurosci, Como, Italy
[2] Univ G dAnnunzio, Dept Pediat, Chieti, Italy
[3] Univ Genoa, G Gaslini Inst, Pediat Neurol & Muscular Dis Unit, Dept Neurosci Rehabil Ophtalmol Genet Maternal &, Genoa, Italy
[4] Univ Perugia, Dept Pediat, I-06100 Perugia, Italy
关键词
Valproic acid; Epileptic syndromes; Metabolic syndrome; Atherosclerosis; INTIMA-MEDIA THICKNESS; VASCULAR RISK-FACTORS; FATTY LIVER-DISEASE; ANTIEPILEPTIC DRUGS; WEIGHT-GAIN; EPILEPTIC PATIENTS; SODIUM VALPROATE; SERUM-INSULIN; HOMOCYSTEINE METABOLISM; CARDIOVASCULAR RISK;
D O I
10.1016/j.eplepsyres.2013.08.016
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Treatment of epileptic patients with valproic acid (VPA) may be associated with substantial weight changes that may increase morbidity and impair adherence to the treatment regimen. VPA-induced weight gain seems to be associated with many metabolic disturbances; the most frequent are hyperinsulinemia and insulin resistance, hyperleptinemia and leptin resistance. Patients who gain weight during VPA therapy can develop dyslipidemia and metabolic syndrome that are associated with long-term vascular complications such as hypertension and atherosclerosis. Moreover, an elevation in the levels of uric acid and homocysteine, together with oxidative stress, may contribute to atherosclerotic risk in patients under long-term therapy with VPA. The aim of this review is to discuss the metabolic and endocrine effects of VPA chronic treatment in patients with epilepsy. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 102 条
[1]   Metabolic Alterations During Valproic Acid Treatment: A Prospective Study [J].
Abaci, Ayhan ;
Saygi, Murat ;
Yis, Uluc ;
Demir, Korcan ;
Dirik, Eray ;
Bober, Ece .
PEDIATRIC NEUROLOGY, 2009, 41 (06) :435-439
[2]   Metabolic syndrome - a new world-wide definition. A consensus statement from the international diabetes federation [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
DIABETIC MEDICINE, 2006, 23 (05) :469-480
[3]   Role of valproate across the ages. Treatment of epilepsy in children [J].
Aldenkamp, A. ;
Vigevano, F. ;
Arzimanoglou, A. ;
Covanis, A. .
ACTA NEUROLOGICA SCANDINAVICA, 2006, 114 :1-13
[4]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[5]   HEART-DISEASE MORTALITY AND MORBIDITY IN PATIENTS WITH EPILEPSY [J].
ANNEGERS, JF ;
HAUSER, WA ;
SHIRTS, SB .
EPILEPSIA, 1984, 25 (06) :699-704
[6]   DIFFERENCES IN LIPOLYSIS BETWEEN HUMAN SUBCUTANEOUS AND OMENTAL ADIPOSE TISSUES [J].
ARNER, P .
ANNALS OF MEDICINE, 1995, 27 (04) :435-438
[7]   Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy [J].
Attilakos, Achilleas ;
Papakonstantinou, Evangellos ;
Schulpis, Kleopatra ;
Voudris, Konstantinos ;
Katsarou, Eustathia ;
Mastroyianni, Sotiria ;
Garoufi, Anastasia .
EPILEPSY RESEARCH, 2006, 71 (2-3) :229-232
[8]   Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate [J].
Aydin, K ;
Serdaroglu, A ;
Okuyaz, C ;
Bideci, A ;
Gucuyener, K .
JOURNAL OF CHILD NEUROLOGY, 2005, 20 (10) :848-851
[9]   Antiepileptic drugs and MTHFR Polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients [J].
Belcastro, Vincenzo ;
Gorgone, Gaetano ;
Italiano, Domenico ;
Oteri, Giancarla ;
Caccamo, Daniela ;
Pisani, Laura Rosa ;
Striano, Pasquale ;
Striano, Salvatore ;
Lentile, Riccardo ;
Pisani, Francesco .
EPILEPSIA, 2007, 48 (10) :1990-1994
[10]   Antiepileptic drugs, hyperhomocysteinemia and B-vitamins supplementation in patients with epilepsy [J].
Belcastro, Vincenzo ;
Striano, Pasquale .
EPILEPSY RESEARCH, 2012, 102 (1-2) :1-7